Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Vermillion Lowers Price Target on Public Offering

Vermillion Lowers Price Target on Public Offering

Feb 14, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion lowered the target of its follow-on offering of stock on Friday after the close of the market.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it will register 4.6 million shares of its common stock at $6.49 per share, raising a maximum of almost $29.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Paper Gone

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational Biologist James Taylor Dies

Computational biologist James Taylor has died, according to Johns Hopkins University.

Ever Infected

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

PLOS Papers on Hepatocellular Carcinoma Immune Cells, Regulatory Prostate Cancer Risk SNPs, More

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.